ARL3 Enhances ERα Stability via USP10 Deubiquitination to Promote Endocrine Resistance and Drive Mitochondrial Metabolic Reprogramming in HR+ Breast Cancer
Advanced Science · 2025
DOI: 10.1002/advs.202509769 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Han Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing …. Hauptthemen laut MEDLINE: Breast Neoplasms, Estrogen Receptor alpha, Mitochondria, ADP-Ribosylation Factors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science-Health Joint Medical Scientific Research Project of Chongqing, General Project of Chongqing Natural Science Foundation, Qian De Young Talent Nurturing Project.
Abstract (Originalsprache)
The molecular mechanisms of estrogen receptor α (ERα)‐positive breast carcinogenesis and endocrine resistance remain unclear. This study identifies ADP‐ribosylation factor‐like protein 3 (ARL3) as a key oncogenic regulator overexpressed in ERα‐positive breast cancer cells and tissues. Mechanistically, ARL3 stabilizes ERα as a novel chaperone via direct binding, enhancing ESR1‐driven transcription and cell proliferation. Genetic ablation of ARL3 induces ERα ubiquitination‐dependent degradation, activating mTOR/AMPK pathways and causing mitophagy/mitochondrial dysfunction. ARL3 maintains ERα stability by upregulating USP10, which removes K48/K63‐linked polyubiquitin chains from ERα at the K252 site. In preclinical models, the small‐molecule inhibitor A‐1331852 (targeting ARL3) potently suppresses ERα‐positive tumor growth and synergizes with endocrine therapies. These findings establish ARL3 as a critical regulator of ERα homeostasis via USP10, highlighting its dual role as a biomarker and ARL3‐targeted therapeutic for ERα‐positive breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
- Chongqing Key Laboratory of Tumor Immune Regulation and Immune Intervention, Chongqing, 400010, China.
- Department of Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
- Department of Immunology, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400010, China.
ORCID-Profile: Shengchun Liu
Förderung
- Science-Health Joint Medical Scientific Research Project of Chongqing
- General Project of Chongqing Natural Science Foundation
- Qian De Young Talent Nurturing Project
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Chongqing Postdoctoral Science Foundation
- Graduate Tutor Team Construction Project of Chongqing Medical University
Zitieren
APA
Li, H., Liu, Y., Cai, Z., Li, K., Gao, S., Lan, A., Shu, D., He, K., Liu, X., Peng, Y., Guo, S., Yu, H., Jin, A., Shen, M., & Liu, S. (2025). ARL3 Enhances ERα Stability via USP10 Deubiquitination to Promote Endocrine Resistance and Drive Mitochondrial Metabolic Reprogramming in HR+ Breast Cancer. Advanced Science. https://doi.org/10.1002/advs.202509769
Vancouver
Li H, Liu Y, Cai Z, Li K, Gao S, Lan A, et al. ARL3 Enhances ERα Stability via USP10 Deubiquitination to Promote Endocrine Resistance and Drive Mitochondrial Metabolic Reprogramming in HR+ Breast Cancer. Advanced Science. 2025. doi:10.1002/advs.202509769
BibTeX
@article{Li2025,
author = {Li, Han and Liu, Yang and Cai, Zehao and Li, Kang and Gao, Shun and Lan, Ailin and Shu, Dan and He, Kuan and Liu, Xin and Peng, Yang and Guo, Shipeng and Yu, Haochen and Jin, Aishun and Shen, Meiying and Liu, Shengchun},
title = {ARL3 Enhances ERα Stability via USP10 Deubiquitination to Promote Endocrine Resistance and Drive Mitochondrial Metabolic Reprogramming in HR+ Breast Cancer},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202509769}
}
EUVIMED